CD8+ Tregs exert their unique therapeutic potential and advantages by secreting immunosuppressive factors and specifically regulating immune responses, thereby alleviating GVHD while maintaining the GVL effect. However, research on CD8+ Tregs in AML is limited. This evidence concerns the gene CD8A and acute myeloid leukemia.